TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06746831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-(+)-methamphetamine
Description: 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-(+)-methamphetamine
Description: 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-(+)-methamphetamine
Description: 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-methamphetamine
Description: 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-methamphetamine
Description: 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-methamphetamine
Description: 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1:1 racemic mixture of two isomers
Description: 15 mg R-Meth + 15 mg S-Meth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1:1 racemic mixture of two isomers
Description: 15 mg R-Meth + 15 mg S-Meth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1:1 racemic mixture of two isomers
Description: 15 mg R-Meth + 15 mg S-Meth
Study: NCT06745973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-003
Description: Intravenous (IV) infusion.
Study: NCT06746623

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Enrolled participants will complete Esocheck/Esoguard and diagnostic upper endoscopy.
Description: Esocheck (EC)/Esoguard (EG): EC is a encapsulated balloon device available commercially from Lucid Diagnostics (New York, NY). EG assay uses bisulfite sequencing for detection of aberrant methylation in the vimentin and cyclin A1 genomic loci, respectively.~EGD (upper endoscopy): EGD will be performed by gastroenterologists practicing in the Louis Stokes Cleveland VA Medical Center Endoscopy laboratories on the same day when EC/EG is performed.
Study: NCT06746610

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Genetic Screening for Monogenic Diabetes
Description: This intervention involves genetic testing for monogenic diabetes (MDM) in recruited participants. The testing includes either a panel test specifically targeting genes associated with monogenic diabetes or whole exome sequencing (WES) to comprehensively identify genetic variants linked to MDM.~Precise diagnosis and treatmen：~1. The clinical trial of individualized treatment was carried out for the individuals with diabetes with HNF1A mutation.~2. The research team will closely follow up individuals with GCK mutation diabetes after suspending the current hypoglycemic drugs, and evaluate their clinical glucose metabolism related indicators.~3. Observe the dosage of sulfonylurea drugs used in individuals with different disease course and pancreatic function, and observe the impact of disease course and pancreatic function on the success rate of oral drug replacement.
Study: NCT04789044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-001
Description: • PEG fusion is the application of a polyethylene glycol (PEG) using a combination of sequenced reagents to a freshly performed nerve coaptation, or neurorrhaphy, to allow the axonal membranes of the proximal and distal axonal stumps to fuse back together and re-establish full axonal continuity.
Study: NCT05748210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom management mobile health application with personalised support
Description: Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience.
Study: NCT06190886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-912
Description: Investigation Product Monotherapy
Study: NCT05165888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication and Bias Mitigation Training
Description: Training to improve communication skills and reduce the effect of racial bias on clinician communication behavior

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication skills training
Description: Training to improve communication skills between physicians and caregivers.
Study: NCT05702853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide injection
Description: 500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide injection
Description: 500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3
Study: NCT05377489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-GRT7039
Description: RTX-GRT7039 monoarticular injections or bilateral intra-articular injections.
Study: NCT06356519

Intervention type: DRUG
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w
Study: NCT04852770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial-Based Cognitive Therapy
Description: TBCT is an approach that includes psychoeducation and cognitive restructuring techniques concerning automatic thoughts, underlying assumptions and core beliefs related to the traumatic events. It is conducted in a therapeutic setting that makes use of experiential techniques, allowing the patient to refer to him/herself in the third person and thus taking distance from him or herself. One of TBCT techniques for dealing with guilt and shame, emotions that provoke great limitation to patients with PTSD, is the participation grid (PG). Another important technique is the consensual role-play (CRP), designed to help patients resolve ambivalence and make decisions. In addition, the most important TBCT technique, the Trial, was developed to help patients change dysfunctional negative core beliefs. Therapists who will conduct this approach have a specialization level in CBT. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Health Promotion
Description: The MBHP protocol is a structured program developed over 8 sessions, in group, where participants (8-15 people) meet every week for 2 hours (standard duration of one session), to experience the concepts and techniques of mindfulness. Participants are also given suggestions of daily activities to be implemented at home or in the workplace, that last in average 15-20 minutes, but may last up to 45 minutes in the case of more motivated and compliant participants. They are also encouraged to incorporate the idea of Mindfulness in their daily lives (the so-called informal practice), so that all daily activities somehow become opportunities to practice Mindfulness. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive psychotherapy
Description: PPT is the clinical and therapeutic work derived from PP. PPT consists of 15 specific practices that have been empirically validated, either separately, or in conjunction with two or three practices. After empirical validation, these practices were organized in a cohesive protocol of 15 sessions called PPT. Many of these practices have been studied through online interventions. In the present study, the protocol will be reduced to 14 sessions, with sessions called positive relationships, positive communication, and practical wisdom removed. It was understood that the other 12 would be more easily adapted to the moment of the study. (DUCKWORTH; STEEN; SELIGMAN, 2005; MONGRAIN; ANSELMO-MATTHEWS, 2012; RASHID; SELIGMAN, 2019). In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
Study: NCT05929131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: discharge instructions with pamphlet
Description: Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before the parents in the control group are discharged from the pediatric emergency service, in the second group (intervention group with brochure) in accordance with the guidelines of the American Academy of Pediatrics (2020), the parents will be told with the brochure giving the same information about fever in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: discharge instructions with video
Description: Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before parents in the control group are discharged from the pediatric emergency service, a short 2-minute video will be shown to the American Academy of Pediatrics (2020) guidelines (intervention group with video) giving the same information about high fever to patients in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: verbal discharge instructions only
Description: Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Parents in the control group will receive the usual verbal information and advice on high fever management in accordance with the guidelines of the American Academy of Pediatrics (2020) prior to discharge from the pediatric emergency service. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
Study: NCT06026709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EmoEase
Description: The online interventionEmoEase integrates two distinct trainings for anxiety and depression. Each training includes approximately twenty 10-minute sessions, and each are centered around different themes. These two trainings will be delivered through a WeChat Mini Program.
Study: NCT05536076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypercapnia treatment
Description: Intermittent hypercapnia treatment five days per week for two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypercapnia treatment
Description: Intermittent hypercapnia treatment five days per week for two weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypercapnia treatment
Description: Intermittent hypercapnia treatment five days per week for two weeks.
Study: NCT05702853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide injection
Description: 500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Injection
Description: 30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3
Study: NCT06450262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
Description: 1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synjardy® 12.5mg/1000mg film-coated tablets
Description: 1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
Study: NCT04875663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
Study: NCT05748210

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Symptom management mobile health application with personalised support
Description: To ensure the equity of access to a potentially desirable and effective intervention (i.e., mHeath app for symptom management), participants in the wait-list control group will be invited to receive the same intervention as participants in the intervention group after the completion of all assessments on a voluntary basis.
Study: NCT05536115

Intervention type: DEVICE
Intervention: Alveogyl
Description: The patients will be treated by Alveogyl. Global treatment protocol (curettage, cleaning, local anaesthesia etc.) of the dry socket is at the discretion of the Investigator.~Alveogyl is used as an alveolar dressing. Placement of Alveogyl (about 0.2 g of paste) into the dental socket is done according to its instruction for use by a dental professional only.
Study: NCT06234514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jueling Mingmu decoction
Description: Jueling Mingmu decoction comprises stone cassia, grass cassia, Leonurus, chrysanthemum, red peony, Schizonepeta, poria, plantago, salvia miltiorrhiza, rice bud, licorice. It is designed to clear liver heat, promote diuresis, activate blood circulation, strengthen the stomach, and harmonize spleen functions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal injections of 0.5mg ranibizumab
Description: Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
Study: NCT06053931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: white noise music
Description: Before the mother starts breastfeeding her baby, white noise music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=5NFHiKMCPvw\&t=6478s).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lullaby music
Description: Before the mother starts breastfeeding her baby, lullaby music will be turned on to help the baby relax during 2 minutes and during the breastfeeding process, music will be played to the baby and mother for approximately 15 minutes.~(https://www.youtube.com/watch?v=h0QO8bgysPg)
Study: NCT05335681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WARM SHOWER APPLICATION
Description: Experimental group; At least when the cervical opening is 4 cm (Latent phase) and 7 cm (Active phase) While the 20-minute hot shower (37 °C) intervention was performed, the control group only will receive standard care. hot shower; sacrum, lower abdomen and groin areas will be applied. Since possible complications may be encountered, pregnant women The researcher will be accompanied and sit safely in the chair. will be provided. VAS scale twice, before and after the intervention will be applied. Birth satisfaction scale before discharge will be applied.
Study: NCT05788094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose)
Description: * Dihydroartemisinin-Piperaquine will be purchased as Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China). One tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine (i.e. a 1:8 ratio). A weight-based regimen containing a total dose of approximately 7 mg/kg DHA and 55 mg/kg piperaquine given in 3 divided doses once daily.~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine plus Tafenoquine (450 mg adult dose)
Description: * Chloroquine will be dosed as a 25 mg/kg base given in divided doses of 10 mg/kg orally on days 0 and 1, and in 5 mg/kg dose on day 2. Tablets will be obtained from Government Pharmaceutical Organization (GPO) in Bangkok, Thailand and supplied as 250 mg tablets (155.3 mg base).~* Tafenoquine KODATEF® 150 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)
Description: * Artemether-Lumefantrine will be given at a standard dose of 20/120 mg twice daily for three days. (AL will be purchase from Novartis Pharma Services AG- Lichtstrasse 35, CH-4056 Basel, Switzerland.)~* Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given.
Study: NCT06680024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal tube
Description: Intercostal tube drainage as a first management of second stage empyema
Study: NCT06234514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal injections of 0.5mg ranibizumab
Description: Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
Study: NCT05962736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The patients received a total of 24 sessions of treatment for 8 weeks, 3 sessions a week, starting from the postoperative 1st day after thorakaotomy. Each treatment session lasts between 60 and 90 minutes.
Study: NCT05905302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forced and Voluntary Exercise
Description: Participants will complete a forced exercise (FE) and voluntary exercise (VE) session. Forced exercise is a mode of high intensity exercise in which voluntary exercise rate is augmented, but not replaced. Voluntary exercise is standard stationary cycling. FE and VE exercise sessions will be Off antiparkinsonian medication. The order in which exercise session is conducted first will be randomized. Bilateral neural activity of the STN will be continuously recorded for 130 minutes (pre, during FE or VE and post-exercise).
Study: NCT05670184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD
Description: Single dose of LSD (50 µg) will be administered in a small amount of alcohol (ethanol, 2ml/95% Vol.) orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Description: Identical ampules containing pure ethanol without the investigational product will be used (1mL ethanol, 95% Vol.).
Study: NCT04657991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Encorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib
Study: NCT04855799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aquamin
Description: Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
Study: NCT05656040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously
Study: NCT06680024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video assisted thoracoscope
Description: Video assisted thoracoscopic surgery as a first management for second stage empyema
Study: NCT06681480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: figure-of-eight active rTMS coil device
Description: rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains with a total of 15000 pulses during 5 weekdays at low frequency 0,5Hz Device: figure-of-eight active rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil, optic navigation system
Study: NCT05656040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: MK-2060 lyophilized powder diluted in normal saline and administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline administered subcutaneously
Study: NCT05064085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Participants will be given Cemiplimab 350 mg IV day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Participants will be given Cemiplimab 350 mg IV day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will take Capecitabine at 2 dose levels: 800 mg/m\^2 and 1000 mg/m\^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will take Capecitabine at 2 dose levels: 800 mg/m\^2 and 1000 mg/m\^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.